Oxford Biomedica ups revenue forecast as AstraZeneca lifts vaccine output
AstraZeneca
10,422.00p
17:15 23/12/24
1.62%
166.00p
Gene and cell therapy group Oxford Biomedica on Tuesday doubled annual earnings guidance after pharmaceutical giant AstraZeneca ordered more Covid-19 vaccines.
FTSE 100
8,102.72
17:14 23/12/24
n/a
n/a
FTSE 250
20,419.09
17:09 23/12/24
n/a
n/a
FTSE 350
4,471.06
17:09 23/12/24
n/a
n/a
FTSE All-Share
4,428.73
16:44 23/12/24
n/a
n/a
Oxford Biomedica
425.00p
16:35 23/12/24
-0.35%
-1.50p
Pharmaceuticals & Biotechnology
20,005.17
17:09 23/12/24
1.24%
244.05
Oxford Biomedica, which has an 18-month supply deal with AstraZeneca to make its AZD1222 vaccine, lifted forecasts for expected cumulative revenues to more than £100m by end-2021 from more than £50m.
As a result, Oxford Biomedica said it expected 'significant growth' in annual operating earnings for the year to end-December.